Status:
COMPLETED
Symptom Identification and Management in Patients With Hematological Malignancy During Follow-up Care
Lead Sponsor:
Rigshospitalet, Denmark
Collaborating Sponsors:
Novo Nordisk A/S
Conditions:
Hematologic Malignancy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The aim is to study the effect of a systematic approach to symptom identification and management with disease specific and clinically developed PRO (HM-PRO) with a 12 month follow up in outpatient car...
Detailed Description
Design: A two-arm prospective randomized controlled trial. Population: Patients diagnosed with chronic myeloid leukemia (CML), clonal cytopenia of unknown significance (CCUS), myelodysplastic syndrom...
Eligibility Criteria
Inclusion
- adults \> 18 years
- diagnosed and undergoing follow up for a hematological malignancy in the outpatient clinic, Rigshospitalet
- The patients can be included approximately six months after initial diagnosis if in stable condition.
- able to manage an e-mail account
Exclusion
- Patients who do not understand, read and speak Danish and/or have cognitive/psychiatric disorders not compatible with inclusion in a clinical study.
Key Trial Info
Start Date :
February 8 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2023
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT04757545
Start Date
February 8 2021
End Date
February 1 2023
Last Update
November 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept. of Hematology
Copenhagen, Denmark, 2100